Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma

Inclusion Criteria: * \>= 18 years of age * Preoperative imaging characteristics consistent with brain glioblastoma (magnetic resonance imaging \[MRI\] brain) * Patients who are undergoing neurosurgical resection for treatment of glioblastoma * Ability to understand and willingness to sign an informed consent form * Ability to adhere to the study visit schedule and other protocol requirements Exclusion Criteria: * Prior treatment for glioblastoma * Glioblastoma size less than 5 cm\^3 * Known allergy against amide type of local anesthetics * History of severe cardiac failure (determined by clinical history of less the 3 Metabolic Equivalent of Tasks \[METs\]) * 2nd or 3rd degree heart block (exception: patients with pacemaker) * Concurrent treatment with class I or III antiarrhythmics (phenytoin, procainamide, propranolol, quinidine) or amiodarone use =\< 3 months * History of Wolff-Parkinson-White syndrome, Stokes Adams syndrome, or active dysrhythmia * History of bradycardia * Prior clinical history of severe hepatic impairment or alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 1.55 times of upper normal limit * Prior clinical history of severe renal impairment or estimated glomerular filtration rate (EGFR) \< 30ml/min * Uncontrolled seizure disorder * Acute porphyria * Patients requiring an awake fiberoptic intubation due to administration of additional lidocaine * Pregnant or lactating women * Any condition that would prohibit the understanding or rendering of informed consent * Any medical condition including additional malignancies, laboratory abnormalities, or psychiatric illness that in the opinion of the investigator would prevent the subject from participating and adhering to study related procedures * Uncontrolled concomitant disease that in the opinion of the investigator would interfere with the patient's safety or compliance on trial